论文部分内容阅读
目的研究混合型肝癌(cHCC-CC)的临床病理特征及预后。方法收集2003年1月至2010年12月在我院经手术病理检查确诊的15例混合型肝癌患者临床病理及随访资料,分析混合型肝癌的临床病理特征、手术治疗后生存率,探讨混合型肝癌预后相关的影响因素。结果 cHCC-CC的HBsAg(+)、血清AFP及肝硬化和HCC有较大的相似性(P>0.05),但与CC有显著的差异(P<0.05);在门脉侵犯、淋巴结转移及包膜完整方面,cHCC-CC与HCC有显著差异(P<0.05);三组病人1年、3年累积存活比率比较有显著差异(P<0.05)。结论混合型肝癌的进展及预后较肝细胞癌和肝内胆管细胞癌差。其术前确诊仍较为困难。
Objective To study the clinicopathological features and prognosis of mixed liver cancer (cHCC-CC). Methods Clinical data of 15 patients with mixed hepatocellular carcinoma confirmed by pathological examination in our hospital from January 2003 to December 2010 were collected. The clinicopathologic features and survival rate of patients with mixed hepatocellular carcinoma were analyzed. The mixed type Influencing factors of prognosis of liver cancer. Results There was a significant difference between HBsAg (+), serum AFP, cirrhosis and HCC in cHCC-CC (P> 0.05), but not in CC (P <0.05) There was a significant difference (P <0.05) between cHCC-CC and HCC in one-year and three-year cumulative survival rate in three groups of patients with intact capsule. Conclusion The progress and prognosis of HCC are worse than that of HCC and intrahepatic cholangiocarcinoma. The preoperative diagnosis is still more difficult.